Revisiting the Stopping Rule for Hepatitis C Genotype 1 Patients Treated with Peginterferon Plus Ribavirin

BACKGROUND: The current stopping rule for peginterferon/ribavirin therapy in hepatitis C virus genotype-1 (HCV-1) patients is based on an early virological response (EVR, defined as >2 log(10) viral reduction at treatment week 12). We aimed to explore rapid stopping rules at week 4. METHODS: We r...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Ming-Lung, Liu, Chen-Hua, Huang, Chung-Feng, Tseng, Tai-Chung, Huang, Jee-Fu, Dai, Chia-Yen, Lin, Zu-Yau, Chen, Shinn-Cherng, Wang, Liang-Yen, Juo, Suh-Hang Hank, Chuang, Wan-Long, Kao, Jia-Horng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528729/
https://www.ncbi.nlm.nih.gov/pubmed/23284866
http://dx.doi.org/10.1371/journal.pone.0052048

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528729/
https://www.ncbi.nlm.nih.gov/pubmed/23284866
http://dx.doi.org/10.1371/journal.pone.0052048

Ejemplares similares